Articles Archives | DelveInsight Business Research Skip to main content
delveinsight blog
  • ABOUT
    • About Us
    • Our Leadership
    • Our Clients
  • CAPABILITIES & SOLUTIONS
    • Reports
    • Competitive Intelligence
    • Case Study
  • CONSULTING SERVICE
  • REPORT STORE
  • MEDIA
    • Blog
    • Press Releases
    • White Papers / Newsletter
    • Events
  • CAREER
  • CONTACT US
  • Report Store
Healthcare blog

Category: Articles

Dec 13 Fragile X Syndrome Market

Fragile X Syndrome Market

Dec 13, 2019Dec 13, 2019 DelveInsight Leave a comment

AI-driven treatment approach and growing Fragile X Syndrome market size Healx Pharma has recently partnered with Boehringer Ingelheim to advance the treatment market and invest in…

Read More
Dec 9 Are Rare diseases truly Rare?

Are Rare diseases truly Rare?

Dec 9, 2019Dec 14, 2019 DelveInsight Leave a comment

Rare diseases, as the name depicts, affect only a small number of people compared to the other disease. Worldwide, one out of 15 persons could be…

Read More
Dec 6 Hype over Gene Therapy: Challenges and Opportunities

Hype over Gene Therapy: Challenges and Opportunities

Dec 6, 2019Dec 14, 2019 DelveInsight Leave a comment

Gene therapy is one of the hottest topics of biotechnology’s vertical in this century. Once considered incurable genetic disorders, now have a cure that is cent…

Read More
Dec 5 Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval

Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval

Dec 5, 2019Dec 5, 2019 DelveInsight Leave a comment

Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS. Reblozyl ((luspatercept-aamt)…

Read More
Dec 4 The Regulatory process for drug approval in the MENA region

The Regulatory process for drug approval in the MENA region

Dec 4, 2019Dec 4, 2019 DelveInsight Leave a comment

The MENA (the Middle East and North Africa) region is mostly an untouched market, which is an impetus for potential development and lucrative growth in the…

Read More
Dec 2 Chronic Refractory Cough Market landscape: A new approach to treating cough

Chronic Refractory Cough Market landscape: A new approach to treating cough

Dec 2, 2019Dec 2, 2019 DelveInsight Leave a comment

When cough seems everlasting, mortifying, and excruciating, it is high time to consult a physician as you might be stricken by chronic cough, which can be…

Read More
Nov 29 Alzheimer’s Disease Market Infographic

Alzheimer’s Disease Market Infographic

Nov 29, 2019Nov 29, 2019 DelveInsight Leave a comment

It’s is the end of Alzheimer’s Awareness Month, but our hope for a cure for this disease will not end. They may not remember us, but…

Read More
Nov 29 UREA CYCLE DISORDER – A LOST ENZYME may lead to FATAL RISKS

UREA CYCLE DISORDER – A LOST ENZYME may lead to FATAL RISKS

Nov 29, 2019Nov 29, 2019 DelveInsight Leave a comment

Do you feel sleepy or fussy? Do you suffer from seizures or breathing problem? And your body temperature is mostly low?You should get it checked, as…

Read More
Nov 25 How Gene therapy is changing the Beta-thalassemia Treatment outlook?

How Gene therapy is changing the Beta-thalassemia Treatment outlook?

Nov 25, 2019 DelveInsight Leave a comment

Beta thalassemia, globally affects almost 288,000 people, with an incidence of 60,000 cases every year. A rare monogenic genetic disease, beta-thalassemia is caused by more than…

Read More
Nov 22 The long journey of Biosimilars: Is it an emerging opportunity?

The long journey of Biosimilars: Is it an emerging opportunity?

Nov 22, 2019Dec 2, 2019 DelveInsight Leave a comment

Biologics are not new drugs, their use as a medicine has been around for over a century. The first use of Biologic drug dates back to…

Read More

Posts navigation

1 2 … 29 Older posts

Recent Posts

  • Fragile X Syndrome Market
  • Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition
  • Gaucher disease Market: Pipeline and Future Trends
  • Acquisition of ArQule; Synthorx; and Zentalis nabs a raise
  • Are Rare diseases truly Rare?

Browse by Category

  • Anti-coagulants (8)
  • API Business Opportunity (5)
  • Articles (285)
  • Atrial Fibrillation (6)
  • Business Consultant (449)
    • Pharma Consultant (430)
  • Chimeric Antigen Receptor (CAR) T-cell Therapy (7)
  • CNS Indications (1)
  • CVS Indications (4)
  • DelveInsight's Drug Report (154)
  • DelveInsight's Indication Pipeline Reports (69)
  • DelveInsight's Oncology based Reports (47)
  • Gene Therapy Products (31)
  • Infographics (40)
  • new therapeutic target (5)
  • Newsletter (2)
  • Notizia (156)
  • Oncology based Indications (11)
  • Orphan market (5)
  • PD-1 and PD-L1 inhibitors (5)
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (1)
  • Pulmonary arterial hypertension (1)
  • Rising of Orphan Drug Development (3)
  • Snippets (128)
  • Specialized Reports (15)
  • The Business Cocktail (140)
  • Uncategorized (61)
  • Venous Thromboembolism (3)

Archives

  • December 2019 (12)
  • November 2019 (24)
  • October 2019 (27)
  • September 2019 (23)
  • August 2019 (22)
  • July 2019 (25)
  • June 2019 (30)
  • May 2019 (29)
  • April 2019 (29)
  • March 2019 (27)
  • February 2019 (20)
  • January 2019 (18)
  • December 2018 (19)
  • November 2018 (26)
  • October 2018 (21)
  • September 2018 (20)
  • August 2018 (26)
  • July 2018 (13)
  • June 2018 (5)
  • May 2018 (8)
  • April 2018 (6)
  • March 2018 (14)
  • February 2018 (11)
  • January 2018 (15)
  • December 2017 (8)
  • November 2017 (13)
  • October 2017 (8)
  • September 2017 (14)
  • August 2017 (13)
  • July 2017 (9)
  • June 2017 (14)
  • May 2017 (20)
  • April 2017 (19)
  • March 2017 (24)
  • February 2017 (21)
  • January 2017 (23)
  • December 2016 (22)
  • November 2016 (23)
  • October 2016 (17)
  • September 2016 (21)
  • August 2016 (17)
  • May 2016 (4)
  • March 2016 (8)
  • February 2016 (3)
  • January 2016 (7)
  • November 2015 (1)
  • October 2015 (1)
  • September 2015 (2)
  • August 2015 (2)
  • July 2015 (8)
  • June 2015 (4)
  • May 2015 (1)
  • April 2015 (5)
  • March 2015 (6)
  • February 2015 (2)
  • January 2015 (5)
  • December 2014 (17)
  • November 2014 (2)
  • September 2014 (1)
  • August 2014 (7)
  • July 2014 (7)
delveinsight


Quick Links

  • About
  • Capabilities & Solutions
  • Report Store
  • Media
  • Career
  • Contact Us

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Tweets by @DelveInsight

Copyright © 2019 Delveinsight.

  • Sitemap
  • Terms & Conditions
  • Privacy policy